bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress - Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust ...

Gene-editing specialist Bluebird Bio (NASDAQ: BLUE) has been making plenty of noise since 2019, which is when it first earned marketing authorization for one of its breakthrough therapies, ...

While most stocks delivered great returns in 2019, bluebird bio's (BLUE) shares fell 11%. And despite a nice upswing to start off the new year, the stock is close to the level it started 2020 after ...

The small-cap manufacturer is benefiting from an environmentally friendly trend. For context, let's review the company's fourth-quarter 2019 earnings report, released Wednesday, keeping in mind that ...

The past few years have been harsh on Bluebird Bio (NASDAQ: BLUE). The rare-diseases-focused, gene-therapy specialist ran into a series of clinical and regulatory headwinds, which played a major role ...

- First conditional approval of ZYNTEGLO TM (autologous CD34+ cells encoding β A-T87Q-globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have ...